BIOVIE INC.

BIVISEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1580149

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$23.1M	$33.3M	$17.3M	$2.5M	$1.2M
Selling, General and Administrative Expense	$8.8M	$11.6M	$9.8M	$4.6M	$1.3M
Operating Expenses	$32.2M	$45.1M	$27.3M	$138.1M	$2.7M
Operating Income (Loss)	-$32.2M	-$45.1M	-$27.3M	-$138.1M	-$2.7M
Interest Expense	—	$4.3M	$2.2M	$559.5K	$4.8M
Nonoperating Income (Expense)	$59.1K	-$5.2M	—	—	—
Net Income (Loss) Attributable to Parent	-$32.1M	-$50.3M	-$26.1M	-$130.2M	-$16.7M
Earnings Per Share, Basic	-$73.05	-$15.47	-$1.06	-$14.82	-$6.85
Earnings Per Share, Diluted	-$73.05	-$15.47	-$1.06	-$14.82	-$6.85

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$25.2M	$35.1M	$20.1M	$6.0M	$2.1M
Assets, Current	$24.0M	$34.0M	$18.8M	$4.6M	$413.0K
Cash and Cash Equivalents, at Carrying Value	$23.8M	$19.5M	$18.6M	—	—
Liabilities	$9.7M	$19.8M	$16.4M	$996.4K	$23.6M
Liabilities, Current	$9.4M	$14.5M	$4.2M	$996.4K	$23.5M
Long-term Debt, Excluding Current Maturities	—	—	—	—	$62.5K
Accounts Payable, Current	$3.6M	$3.5M	$2.4M	$996.4K	$1.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$27.9M	-$40.3M	-$19.0M	-$10.5M	-$1.6M
Net Cash Provided by (Used in) Investing Activities	$14.5M	-$14.3M	-$14.3M	—	—
Net Cash Provided by (Used in) Financing Activities	$17.8M	$55.4M	$33.1M	$14.9M	$1.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)